The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Barclays upgrades Natera stock to Overweight with $200 price target
Barclays has upgraded Natera's stock rating to Overweight with a $200 price target, citing the company's impressive 158% return over the past year and its successful expansion into new markets, particularly in NIPT and MRD testing. Natera reported a record Q3 revenue of $439.8 million, a 64% increase from the previous year, and is gaining market share in Organ Health. Despite a setback in a lawsuit against Guardant Health, Natera's management remains confident in sustaining growth through its own capabilities.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.